Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

NCT02784015 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-09-18

No results posted yet for this study

Summary

To evaluate the treatment outcome of unresectable soft tissue sarcoma using response based treatment

Conditions

  • Unresectable Localized Soft Tissue Sarcoma

Interventions

DRUG

Cisplatin

DRUG

Etoposide

DRUG

Doxorubicin

DRUG

Ifosfamide

RADIATION

Radiotherapy

DRUG

Thiotepa

DRUG

Melphalan

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-05-31
Completion
2023-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784015 on ClinicalTrials.gov